Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) is a ubiquitously expressed co-chaperone that plays a critical role in cellular proteostasis and protein quality control. It consists of three distinct domains: an N-terminal dimerization domain, a central tetratricopeptide repeat (TPR) domain, and a C-terminal glutamine-rich region. SGTA interacts with molecular chaperones like HSP70 and HSP90, as well as the BAG6 complex, to capture misfolded or mislocalized hydrophobic proteins in the cytosol and direct them toward either refolding or proteasomal degradation. Additionally, SGTA acts as a key regulator of steroid hormone receptors, particularly the androgen receptor (AR), by binding to its hinge region and retaining it in the cytoplasm, thereby suppressing androgen signaling.
Due to its diverse roles, SGTA is implicated in several pathologies, including hormone-dependent cancers (such as prostate and breast cancer), polycystic ovary syndrome (PCOS), viral infections (by interacting with viral proteins like HIV-1 Vpu and SARS-CoV accessory protein 7a), and neurodegenerative diseases associated with protein aggregation. In therapeutic development, SGTA is considered an attractive target for small-molecule inhibitors and RNA interference therapies. For instance, the natural product derivative methyl gerfelin has been shown to bind SGTA. However, because SGTA is ubiquitously expressed and interacts with numerous cellular proteins, therapeutic targeting presents significant safety challenges, including potential systemic toxicity and unintended alterations in steroid receptor signaling.
Inhibition of SGTA co-chaperone activity and disruption of its protein-protein interactions with chaperones or client proteins
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA).